Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) approved SYNRIBO (omacetaxine mepesuccinate) for Injection to treat adult patients with chronic phase (CP) or accelerated phase (AP) chronic …
Teva Pharmaceutical Industries Limited : Teva Receives Approval For SYNRIBOTM (Omacetaxine Mepesuccinate) for Injection